Company intelligence
CILIATECH - Glaucoma Innovators
Developing a new class of supraciliary implant for treating glaucoma
About CILIATECH - Glaucoma Innovators
CILIATECH is a medtech company specialized in ophthalmology, developing a new class of implant to address the increasing need to treat glaucoma durably with a novel design. Founded in 2017 by ophthalmic surgeon and inventor Dr. Philippe Sourdille and Olivier Benoit, a veteran engineer and biotech entrepreneur, CILIATECH developed the CID (Cilio-scleral Inter-positioning Device) groundbreaking concept ‘CID’ is the first implant in the industry to reduce IntraOcular Pressure (IOP) without needing to access the anterior chamber or create a subconjunctival filtration bleb. The device is implanted as a standalone procedure and in the latest trial has demonstrated efficacy in IOP lowering in both open angle glaucoma (POAG) and in narrow angle glaucoma - the latter is a real industry first. Implantation can be combined with cataract removal too. The company is located near Annecy, France - a beautiful region in the Western Alps which has been described as ‘the Alpine Venice’ www.cilia.tech
Verified activity
Signals from CILIATECH - Glaucoma Innovators
2 published signals
Legal & Regulatory
CILIATECH - Glaucoma Innovators received FDA approval for the Investigational Device Exemption (IDE) application to initiate a feasibility study in the US for their novel INTERCIL Uveal Spacer for glaucoma.
Reported by CILIATECH - Glaucoma Innovators
Research & Knowledge
CILIATECH - Glaucoma Innovators published 2-year clinical data for the Intercil Uveal Spacer in Ophthalmology and Therapy titled A Prospective Evaluation of the 2-Year Efficacy and Safety of INTERCIL: A Uveal Spacer for Open-Angle Glaucoma.
Reported by CILIATECH - Glaucoma Innovators